Keyphrases
Hypertension
100%
Rat Model
100%
Polycystic Ovary Syndrome
100%
Metabolic Perturbation
100%
Dihydrotestosterone
100%
Liraglutide
100%
Type 2 Diabetes Mellitus (T2DM)
18%
Blood Pressure
18%
Sham
18%
Glucagon-like peptide-1 Receptor (GLP-1R)
18%
Twice Daily
9%
Targeted Therapy
9%
Cardiovascular Disease
9%
Area under the Curve
9%
Sprague-Dawley Rats
9%
Long-term Complications
9%
Beneficial Effects
9%
Oral Glucose Tolerance Test
9%
Hypertensive
9%
Metabolic
9%
Cardiovascular System
9%
Mean Arterial Pressure
9%
Endocrine Disorders
9%
Diabetes Disease
9%
Cardiovascular Outcomes
9%
Saline Injection
9%
Women of Reproductive Age
9%
Glucagon-like peptide-1 (GLP-1)
9%
Metabolic Outcomes
9%
Glucose Excursion
9%
Prepubertal Females
9%
Pressure Deficit
9%
Estrus Cycle
9%
Telemeter
9%
Pharmacology, Toxicology and Pharmaceutical Science
Syndrome
100%
Rat Model
100%
Androstanolone
100%
Liraglutide
100%
Scanning Electron Microscopy
18%
Glucagon Like Peptide 1 Receptor Agonist
18%
Non Insulin Dependent Diabetes Mellitus
18%
Prevalence
9%
Sprague Dawley Rat
9%
Glucagon-Like Peptide-1
9%
Endocrine Disease
9%
Cardiovascular Disease
9%
Table Salt
9%
Medicine and Dentistry
Polycystic Ovarian Syndrome
100%
Androstanolone
100%
Liraglutide
100%
Maturity Onset Diabetes of the Young
18%
Blood Pressure
18%
Scanning Electron Microscopy
18%
Glucagon-Like Peptide-1 Agonist
18%
Cardiovascular System
9%
Prevalence
9%
Targeted Therapy
9%
Cardiovascular Disease
9%
Glucagon Like Peptide 1
9%
Mean Arterial Pressure
9%
Oral Glucose Tolerance Test
9%
Body Weight
9%
Endocrine Disease
9%
Estrus Cycle
9%
Cardiovascular System
9%
Table Salt
9%